logo
Six years in storage, ‘Virus' breaks free at last

Six years in storage, ‘Virus' breaks free at last

Korea Herald28-04-2025
A pandemic rom com held hostage by an actual pandemic finds its way to theaters
The irony wasn't lost on anyone at Monday's press conference for the romantic comedy "Virus" -- a film about a fictional pathogen that causes people to fall madly in love was itself quarantined for nearly six years, due to a real pandemic that kept people apart.
"Although there were many twists and turns leading up to the release, I'm thrilled we can finally present the film," director Kang Yi-kwan told reporters at Seoul's Yongsan CGV cinema on Monday. The film, which completed production in late 2019, became an unwitting casualty of timing when the COVID-19 pandemic made releasing a virus-themed work virtually impossible.
Its narrative centers on Taek-sun (Bae Doo-na), a disaffected translator drifting through life, who suddenly blooms after becoming infected with the "Toxovirus" -- a pathogen with a curious symptom: it induces overwhelming happiness and instant love.
The virus places her in the orbit of three men: researcher Soo-phil (Son Suk-ku), who becomes the first infected person; her childhood friend Yeon-woo (Chang Ki-ha); and the brilliant Dr. Lee Kyun (Kim Yoon-seok), the only person capable of developing a cure.
For actor Kim Yoon-seok, the unexpected delay created a surreal disconnect between filming and release. "The world changed between shooting this film and now," he reflected. "Things we imagined -- PCR tests, lab protocols, protective equipment -- suddenly became everyday reality. It felt incredibly strange to watch our fictional scenario materialize in real life."
The film represents a tonal shift for Bae, who has spent much of the past decade in darker genre pieces like "Kingdom," the zombie-historical horror series, and "Stranger," the critically acclaimed investigative thriller.
"After projects involving disasters or intense themes, I missed something soft, warm and bright," she said. "I've always believed that making audiences happy is a major charm of movies."
Bae hesitated to categorize the film as merely a romance, though. "I'm not sure it's a love story per se," she said. "It's more about a person discovering a different side of themselves when their emotional barriers are forcibly opened."
The film marks singer-songwriter Chang Ki-ha's lead acting debut, a challenge he initially balked at. "When I first read the script, there seemed to be too many lines. I didn't think I could do it," he admitted. "Then Kim Yoon-seok called and said, 'Film people know what they're doing. We'll create the environment -- you just come and have fun.'"
Director Kang emphasized how "Virus" offers a refreshing counterpoint to typical infection film conventions. "Most virus narratives are apocalyptic, focusing on societal collapse," he noted. "We wanted to explore a virus that makes people better versions of themselves, and examine it from a personal perspective rather than a macro view of pandemic response."
For Bae, the film's theatrical release remains important despite its long delay. "We shot this specifically for the big screen," she said. "When actors perform for the cinema, we're conscious of how even subtle expressions will read on a large screen.
"Honestly, I wouldn't say you absolutely must watch it in theaters -- it would work anywhere -- but those small details and nuances we crafted specifically for cinema viewing might get lost on smaller devices."
Kim echoed this sentiment in more philosophical terms: "The cinema is another kind of public square. It's where unconnected strangers focus collectively on one experience, creating energy you can't replicate at home."
"Virus" opens nationwide on May 7.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DMZ Docs unveils International, Frontier Competition selections
DMZ Docs unveils International, Frontier Competition selections

Korea Herald

time5 days ago

  • Korea Herald

DMZ Docs unveils International, Frontier Competition selections

Festival selects 18 titles from over 600 submissions, with 45 million won in total prizes The DMZ International Documentary Film Festival (DMZ Docs) has announced the International and Frontier competition lineups for its upcoming 17th edition, presenting works that explore the aftermaths of historical conflict and their broader implications for global communities. A total of 18 titles were selected from over 600 submissions by the festival's programming committee, which includes chief programmer Jang Byung-won, programmer Kang Jin-seok and film critic Lee Seung-min. Ten films will compete in the International Competition and eight in the Frontier section. Highlights from the International Competition include "To the West, in Zapata," a black-and-white Cuban documentary that received the Jury Special Award in Visions du Reel's Burning Lights section. "La jetee, the Fifth Shot," which won the Golden Dove at DOK Leipzig, examines Algeria's colonial past through family archives. Romanian-Korean co-production "Bright Future" draws on footage from the 1989 World Festival of Youth and Students in Pyongyang to offer a counter-narrative to Cold War-era spectacle. Ongoing global conflicts are represented prominently across the selections. "Militantropos" employs direct cinema techniques to examine aspects of the Russia-Ukraine war, while Abbas Fahdel's "Tales of the Wounded Land" documents life in southern Lebanon in the wake of the Israel-Lebanon conflict. The Frontier section showcases formally inventive works that expand the documentary form. Kamal Aljafari's "With Hasan in Gaza" reconstructs footage from 2001 to recover images of people and places now lost in Gaza. "Ancestral Visions of the Future" blends personal narration and poetic imagery to reflect on the filmmaker's own exile from Lesotho during civil unrest. In "New Beginnings," director Billy Luther follows a Vietnam War veteran on California's Native American reservation, exploring the intersection of ecological degradation and intergenerational trauma. Launched in 2009, DMZ Docs has grown into one of Korea's leading documentary festivals. It introduced its current competition format — comprising International, Korean and Frontier sections — in 2023 as part of a broader programming overhaul. The International and Frontier categories will award a combined 45 million won ($32,000) in prizes, including 20 million won for the International Competition Grand Prize, 10 million won for the Jury Special Award and 15 million won for the Frontier Competition Grand Prize. The 2025 edition of DMZ Docs will take place Sept. 11-17 in Paju and Goyang, Gyeonggi Province. Its industry program, DMZ Industry, will run Sept. 12-16 as a co-production and project development platform.

SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate

Korea Herald

time17-07-2025

  • Korea Herald

SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate

SEONGNAM, South Korea, July 17, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. The candidate incorporates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu' to enhance protective efficacy. SK bioscience previously utilized adjuvants in its COVID-19 vaccine, 'SKYCovione', and now seeks to expand this technology to influenza vaccines as part of its broader platform strategy. NBP607B contains an adjuvant developed by the Vaccine Formulation Institute (VFI), a Swiss-based non-profit vaccine research organization. Comprising multiple immune-boosting components, the adjuvant is expected to induce strong immune responses and antibody production in elderly individuals. SK bioscience has proactively conducted non-clinical studies since 2023 and reported promising results. The Phase 1/2 clinical trial is scheduled to begin during the upcoming Northern Hemisphere flu season, enrolling approximately 320 older adults in Korea and abroad. The study will evaluate the vaccine's immunogenicity and safety compared to an approved high-immunogenicity flu vaccine, with interim results expected by 2027. This marks the first attempt by a Korean company to submit an IND to develop a high-immunogenicity influenza vaccine using an adjuvant. If successful, the company plans to leverage the platform for other vaccines and establish a competitive edge in the global high-value vaccine market. The development aligns with global health authorities' increasing recommendations for enhanced flu vaccines in high-risk groups. The U.S. Centers for Disease Control and Prevention (CDC)'s Advisory Committee on Immunization Practices (ACIP) recommends high-dose or adjuvanted influenza vaccines for adults aged 65 and older. The World Health Organization (WHO) also supports the use of adjuvanted vaccines for vulnerable populations. In Korea, the Korea Disease Control and Prevention Agency (KDCA) has indicated that domestically developed high-immunogenicity vaccines may be considered for inclusion in the National Immunization Program (NIP) if they meet appropriate criteria. According to market research firm Mordor Intelligence, the global vaccine market is projected to grow from USD 83.9 billion in 2025 to USD 114.8 billion in 2030, with an average annual growth rate of 6.5%. Demand for high-immunogenicity vaccines is expected to rise continuously due to global aging and the increasing number of immunocompromised individuals and those with chronic illnesses. SKYCellflu, SK bioscience's existing cell-based influenza vaccine, has already been recognized for its innovation. It became the world's first cell-based flu vaccine to receive prequalification (PQ) from the WHO and is currently approved in 11 countries, with supply through international procurement programs by United Nations Children's Fund (UNICEF) and Pan American Health Organization (PAHO). Jaeyong Ahn, CEO of SK bioscience, said, "We believe the combination of our proven SKYCellflu platform and our experience in adjuvanted vaccine development positions us well for success. We aim to establish a differentiated presence in the high-immunogenicity vaccine market while building a flexible platform for future infectious disease preparedness."

New science minister pledges to make Korea AI powerhouse
New science minister pledges to make Korea AI powerhouse

Korea Herald

time17-07-2025

  • Korea Herald

New science minister pledges to make Korea AI powerhouse

Science and ICT Minister Bae Kyung-hoon officially began his tenure on Thursday, becoming the first Cabinet minister to take office under the Lee Jae Myung administration. In his inaugural speech at Sejong Government Complex, Bae pledged to lead a national transformation powered by artificial intelligence and advanced science and technology. 'The future of our nation will depend on how we design strategies and respond to the coming wave of innovation and change,' he said. Bae is one of Korea's leading private-sector AI experts. As the founding president of LG AI Research, the artificial intelligence arm of LG Group, he played a key role in spearheading the development of the conglomerate's hyperscale language model Exaone from December 2020 until he was nominated as the new minister. He also served in key government advisory roles related to AI governance and privacy. He previously held the chief position of the AI technology division at LG Uplus and practiced various AI applications at SK Telecom. Bae has earned a Ph.D. in electronic engineering from Kwangwoon University and completed an executive program for AI: Implications for Business Strategy from the Sloan School of Management at the Massachusetts Institute of Technology. The new minister emphasized that Korea, now standing among the ranks of advanced nations, must break away from outdated approaches to achieve its next goals, including raising the country's potential growth rate to 3 percent and joining the world's top five economic powers. He went on to emphasize the need for a bold transformation, saying, 'We must secure a unique competitive edge that no other country can replicate, and bring about a groundbreaking shift through a national transition rooted in AI and cutting-edge science and technology to enhance efficiency and productivity.' Highlighting AI as the driving force of the new era, Bae said its influence is rapidly permeating all aspects of society beyond industry and the economy. To navigate the shift, he proposed fostering top-tier talent, building an innovation-friendly ecosystem and spearheading a nationwide transformation centered on AI and cutting-edge technologies. He outlined four key policy directions: establishing a robust AI ecosystem, revitalizing the research and development innovation landscape, nurturing world-class talent in AI and science, and addressing pressing challenges closely tied to people's daily lives. "To achieve the vision of becoming one of the world's top three AI powerhouses — the first pledge of the People's Sovereignty Government — we will build a robust AI ecosystem and create an environment where AI is accessible to all,' the minister said. He emphasized the importance of establishing AI and digital infrastructure, enhancing cybersecurity systems, securing foundational AI models, promoting AI transformation and supporting AI semiconductors. Bae also announced plans to restore the grassroots-level basic research initiatives that had been phased out, ensuring stable and sufficient R&D funding. 'We will support the adoption of AI within scientific research itself,' he said. In terms of talent development, Bae proposed enhancing support for young scientists, establishing AI-centered universities, and improving working conditions at government-funded research institutes.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store